553631-05-3

Basic information

• Product Name: 1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE
• Synonyms: 1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE;tert-Butyl 4-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate;1-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE
• CAS NO: 553631-05-3
• Molecular Formula: C₁₆H₂₂FNO₃
• Molecular Weight: 295.352
• Mol File: 553631-05-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(553631-05-3)
• EPA Substance Registry System: 1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE(553631-05-3)

Safety Data

• Hazardous Substances Data: 553631-05-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE is used as a building block for the synthesis of drugs targeting neurological disorders, inflammation, and cancer. Its unique structure and reactivity allow for the development of novel therapeutic agents with potential applications in treating various health conditions.
Used in Agrochemical Industry:
1-N-BOC-4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDINE is used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural products. Its versatile chemical properties enable the creation of effective and environmentally friendly solutions for crop protection and management.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 352-13-6 4-flourophenylmagnesium bromide 
• 225916-39-2 2-(4-fluorophenyl)-5,5-dimethyl-1,3,2-dioxaborinane 
• 1765-93-1 4-fluoroboronic acid 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1004619-24-2 tert-butyl 4-fluoro-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 3888-65-1 4-(4-fluorophenyl)piperidin-4-ol 
• 1004852-93-0 4-fluoro-4-(4-fluoro-phenyl)-piperidine 
• 39795-58-9 4-(4-fluorophenyl)pyridine 
• 1978-61-6 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 1191240-31-9 4-(4-fluorophenyl)-4-(2-pyrrolidin-1-yl-ethoxy)-piperidine-1-carboxylic acid tert-butyl ester 
• 143682-41-1 3-{4-[4-(4-fluorophenyl)-1-(1,2,3,6-tetrahydro)pyridinyl]-1-butyl}-1H-indole 
• 1027077-17-3 1-[4-(4-Fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-4-(1H-indol-3-yl)-butan-1-one 

Relevant articles and documents

Bulky N-Heterocyclic-Carbene-Coordinated Palladium Catalysts for 1,2-Addition of Arylboron Compounds to Carbonyl Compounds

The synthesis of primary, secondary, and tertiary alcohols by the 1,2-addition of arylboronic acids or boronates to carbonyl compounds, including unactivated ketones, using novel bulky yet flexible N-heterocyclic carbene (NHC)-coordinated 2,6-di(pentan-3-yl)aniline (IPent)-based cyclometallated palladium complexes (CYPs) as catalysts is reported. The PhS-IPent-CYP-catalyzed reactions are efficient at low catalyst loadings (0.02–0.3 mol% Pd), and the exceptional catalytic activity for 1,2-addition is attributed to the steric bulk of the NHC ligand. These reactions can yield a wide range of functionalized benzylic alcohols that are difficult to synthesize by classical protocols using highly active organomagnesium or lithium reagents.

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Monoamine Oxidase (MAO-N) Whole Cell Biocatalyzed Aromatization of 1,2,5,6-Tetrahydropyridines into Pyridines

A sustainable MAO-N biocatalyzed process for the synthesis of pyridines from aliphatic tetrahydropyridines (THP) has been developed. Pyridine compounds were synthesized under mild reaction conditions and with high conversion, exploiting MAO-N whole cells as aromatizing biocatalysts. The kinetic profile of the whole cell biocatalytic transformation was finally investigated via in situ 19F NMR.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Ni-catalysed, domino synthesis of tertiary alcohols from secondary alcohols

The use of in situ generated (NHC)-Ni catalytic species (NHC = N-heterocyclic carbene) allows for the synthesis, in short reaction times, of a variety of tertiary alcohols from secondary alcohols through a domino oxidation-addition protocol.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide compounds corresponding to formula I processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment and/or inhibition of pain and other conditions at least partly mediated by the bradykinin 1 receptor

A nickel catalyst for the addition of organoboronate esters to ketones and aldehydes

A Ni(cod)2/IPr catalyst promotes the intermolecular 1,2-addition of arylboronate esters to unactivated aldehydes and ketones. Dlaryl, alkyl aryl, and dialkyl ketones show good reactivity under mild reaction conditions (3) with aryl ether substrates. A Ni(0)/Ni(II) catalytic cycle initiated by the oxidative cyclization of the carbonyl substrate Is proposed.

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.